Revolution Medicines RVMD
NASDAQ RVMD
$199.86 +9.12 (+4.78%)
At close: Sep 24, 2026 · 4:00 PM EDT

Revolution Medicines (RVMD) Net Income towards Common Stockholders (2019 - 2026)

Revolution Medicines (RVMD) posted Net Income towards Common Stockholders of -$644.4 million for Q2 2026, down 41.99% on a QoQ basis from -$453.8 million in Q1 2026, and down 160.05% year-over-year from $1.1 billion in Q2 2025.

Analysis

Revolution Medicines (RVMD) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

Revolution Medicines has reported Net Income towards Common Stockholders for 8 years, with the latest figure at -$644.4 million in Q2 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 160.05% year-over-year to -$644.4 million in Q2 2026; TTM through Jun 2026 was -$1.8 billion, a 117.75% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 billion, down 88.52% from the prior year.
  • Net Income towards Common Stockholders was -$644.4 million for Q2 2026 at Revolution Medicines, down from -$453.8 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$56.5 million in Q4 2022, with the low at -$644.4 million in Q2 2026.
  • Average Net Income towards Common Stockholders over 5 years is -$195.3 million, with a median of -$144.8 million recorded in 2024.
  • The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders slipped 7.27% in 2022, then plunged 185.87% in 2023.
  • Over 5 years, Net Income towards Common Stockholders stood at -$56.5 million in 2022, then slumped by 185.87% to -$161.5 million in 2023, then dropped by 20.45% to -$194.6 million in 2024, then plunged by 87.54% to -$364.9 million in 2025, then tumbled by 76.59% to -$644.4 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$644.4 million (Q2 2026), -$453.8 million (Q1 2026), and -$364.9 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Johnson & Johnson 649.01 Bn 628.25 Bn 17.26 Bn 5.53 Bn
2 AbbVie 468.55 Bn 462.03 Bn 12.70 Bn 3.62 Bn
3 Merck 365.49 Bn 358.40 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 272.39 Bn 265.10 Bn 11.24 Bn 3.26 Bn
5 Astrazeneca 253.18 Bn 247.96 Bn 12.86 Bn 2.51 Bn
6 Amgen 219.53 Bn 205.54 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 187.85 Bn 184.59 Bn 6.22 Bn -10.50 Bn
8 Pfizer 160.56 Bn 149.16 Bn 10.94 Bn -238.00 Mn
9 Vertex Pharmaceuticals 130.81 Bn 122.96 Bn 2.84 Bn 1.10 Bn
10 Revolution Medicines 40.86 Bn 40.86 Bn - -644.37 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -644.37 Mn
Mar 31, 2026 -453.82 Mn
Dec 31, 2025 -364.89 Mn
Sep 30, 2025 -305.21 Mn
Jun 30, 2025 -247.79 Mn
Mar 31, 2025 -213.42 Mn
Dec 31, 2024 -194.57 Mn
Sep 30, 2024 -156.29 Mn
Jun 30, 2024 -133.23 Mn
Mar 31, 2024 -116.00 Mn
Dec 31, 2023 -161.54 Mn
Sep 30, 2023 -108.43 Mn
Jun 30, 2023 -98.30 Mn
Mar 31, 2023 -68.10 Mn
Dec 31, 2022 -56.51 Mn
Sep 30, 2022 -73.33 Mn
Jun 30, 2022 -61.22 Mn
Mar 31, 2022 -57.65 Mn
Dec 31, 2021 -52.68 Mn
Sep 30, 2021 -52.94 Mn
API Access

Revolution Medicines Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=RVMD&period=max&api_key=YOUR_API_KEY